Literature DB >> 4398246

The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901).

B J Alps, M Hill, K Fidler, E S Johnson, A B Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4398246     DOI： 10.1111/j.2042-7158.1971.tb08744.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  6 in total

1.  Anti-arrhythmic properties of the alpha-adrenoceptor blocking drug indoramin.

Authors:  M A James; J V Jones
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

2.  Cardiovascular effects of indoramin in man--a dose ranging study.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 3.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

4.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

5.  Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.

Authors:  V Pierce; N B Shepperson; M H Todd; J F Waterfall
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

6.  Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man?

Authors:  D W Harron; D P Nicholls; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.